本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688050 证券简称：爱博医疗 公告编号：2025-045 爱博诺德（北京）医疗科技股份有限公司 2024年年度权益分派实施公告 重要内容提示： 每股现金红利0.35元（含税） 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/17 | 2025/7/18 | 2025/7/18 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经爱博诺德（北京）医疗科技股份有限公司（以下简称"公 司"或"本公司"）2025 年 6 月 19 日的2024年年度股东会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东 （公司回购专用证券账户除外）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 是否涉及差异化分 ...

Group 1 - The core viewpoint highlights the significant growth and performance of the Kexin Pharmaceutical ETF managed by Jiashi, with a notable increase in trading volume and fund size [2] - As of July 9, the Kexin Pharmaceutical ETF achieved a daily average trading volume of 34.95 million yuan over the past month, ranking first among comparable funds [2] - The fund's size increased by 16.76 million yuan in the past two weeks, also ranking first among comparable funds [2] - The ETF saw a total inflow of 12.84 million yuan over the last ten trading days, indicating strong investor interest [2] - The net value of the Kexin Pharmaceutical ETF rose by 36.83% over the past year, showcasing its strong performance [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [2][4] - On July 9, Shanghai Pharmaceuticals announced an expected net profit of 4.45 billion yuan for the first half of 2025, representing a year-on-year increase of approximately 52% [4] Group 3 - Short-term market expectations for overseas transactions in innovative drugs are high, leading to a continuous rise in valuations [5] - China's innovative drug research and development capabilities are competitive globally, and the trend of innovative drugs going overseas is expected to persist [5] - The commercial health insurance sector in China is anticipated to see significant growth in premium income and payout rates, becoming an important source of funding for innovative drugs [5]

证券代码：688050 证券简称：爱博医疗 公告编号：2025-043 爱博诺德（北京）医疗科技股份有限公司 2021 年限制性股票激励计划首次授予部分第四个归属期 及预留授予部分第三个归属期归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 265,032股。 本次股票上市流通总数为265,032股。 本次股票上市流通日期为2025 年 7 月 2 日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司有关业务规则的规定，爱博诺德（北京）医疗科技股份有限公 司（以下简称"公司"或"本公司"）于近日收到中国证券登记结算有限责任公司 上海分公司出具的《证券变更登记证明》，公司已完成 2021 年限制性股票激励计 划（以下简称"本激励计划"）首次授予部分第四个归属期及预留授予部分第三个 归属期的股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序和信息披露情况 （一）2021 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-044 爱博诺德（北京）医疗科技股份有限公司 关于调整 2024 年年度利润分配现金分红总额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 现金分红总额调整情况：爱博诺德（北京）医疗科技股份有限公司（以下 简称"公司"）2024 年年度利润分配拟向全体股东每 10 股派发现金红利 3.50 元 （含税）不变，不进行资本公积转增股本，亦不派送红股，拟派发现金分红总额 由 67,548,370.05 元（含税）调整为 67,641,131.25 元（含税）。 ● 本次调整原因：因公司 2021 年限制性股票激励计划首次授予部分第四个归 属期及预留授予部分第三个归属期归属的 265,032 股限制性股票已于 2025 年 6 月 26 日在中国证券登记结算有限责任公司上海分公司完成登记手续，公司可参与利 润分配的总股本新增 265,032 股，公司按照维持每股分配比例不变的原则，对公 司 2024 年年度利润分配现金分红总额进行相应调整。 ...

Group 1 - The article highlights that three public funds, namely ICBC Credit Suisse Fund, Yongying Fund, and E Fund, have reported paper losses from their locked shares in recent private placements, totaling approximately 6.6 million yuan [1][2] - Specifically, ICBC Credit Suisse Fund has a loss of about 296.07 thousand yuan, Yongying Fund has a loss of approximately 249.02 thousand yuan, and E Fund has a loss of around 114.76 thousand yuan [1][2] - The funds participated in one or more private placement projects, with the number of locked stocks being 1 for ICBC Credit Suisse and Yongying Funds, and 3 for E Fund [1][2] Group 2 - The data indicates that ICBC Credit Suisse Fund invested 24.477 million yuan in a private placement for Aibo Medical (688050.SH), with the lock-up period starting on May 12, 2025, and ending on November 13, 2025 [3] - Yongying Fund also participated in the same private placement for Aibo Medical, investing 20.587 million yuan, with identical lock-up dates [4] - E Fund engaged in two private placements, including Aibo Medical and Zhongtung High-tech (000657.SZ), investing 9.4871 million yuan in Aibo Medical, with the same lock-up period [5] Group 3 - The article notes that the primary source of the current public fund losses is linked to the private placement investments, which inherently carry risks due to the lock-up periods and market volatility [6] - It is mentioned that the attractiveness of private placements for companies is diminishing, as they may incur higher costs compared to other financing methods, such as debt financing, which does not dilute existing shareholders' equity [7] - Current market conditions, including low interest rates for bank loans and bond issuances, further reduce the incentive for companies to opt for private placements [7]

Meeting Overview - The shareholders' meeting of Aibo Medical was held on June 19, 2025, at the company's headquarters in Beijing [1] - A total of 238 ordinary shareholders attended, holding 79,668,669 voting rights, which represents 41.2801% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved with high support, including: - Proposal 1: 79,255,028 votes in favor (99.4807%) [1] - Proposal 2: 79,258,590 votes in favor (99.4852%) [1] - Proposal 3: 79,222,750 votes in favor (99.4402%) [1] - Proposal 4: 79,269,768 votes in favor (99.4993%) [1] - Proposal 5: 36,828,822 votes in favor (98.8358%) [1] - Proposal 6: 79,222,617 votes in favor (99.4401%) [1] Board Elections - The following individuals were elected as non-independent directors: - Jie Jiangbing [3] - Wang Zhao [3] - Jia Baoshan [3] - Chen Yong [3] - Zhang Jian [3] - The following individuals were elected as independent directors: - Wang Jing [3] - Li Xunhu [3] - Wang Dongsheng [3] Legal Compliance - The meeting's procedures and voting were confirmed to comply with relevant laws and the company's articles of association by the witnessing lawyers [3]

Group 1 - The legal opinion letter confirms that the 2024 annual general meeting of Aibono Medical Technology Co., Ltd. was convened and conducted in accordance with relevant Chinese laws and regulations, as well as the company's articles of association [3][4][6] - The meeting utilized a combination of on-site and online voting, with the on-site meeting held at the company's headquarters and online voting available on June 19, 2025, from 9:15 AM to 3:00 PM [3][4] - A total of 238 shareholders participated in the voting, representing 79,668,669 shares, which accounts for 41.2801% of the total voting shares [4][6] Group 2 - The meeting's agenda included 12 proposals, with specific focus on the annual reports, financial budget, and the election of board members, including both independent and non-independent directors [6] - Proposals 11 and 12 were subject to cumulative voting, and all candidates were successfully elected [6] - The special resolution regarding the cancellation of the supervisory board and amendments to the articles of association was passed with more than two-thirds of the voting shares in favor [6]

爱博诺德（北京）医疗科技股份有限公司 章 程 二〇二五年六月 | 第一章 | 总则 4 | | --- | --- | | 第二章 | 经营宗旨和范围 5 | | 第三章 | 股份 5 | | 第一节 | 股份发行 6 | | 第二节 | 股份增减和回购 8 | | 第三节 | 股份转让 9 | | 第四章 | 股东和股东会 10 | | 第一节 | 股东 10 | | 第二节 | 股东会的一般规定 13 | | 第三节 | 股东会的召集 18 | | 第四节 | 股东会的提案与通知 20 | | 第五节 | 股东会的召开 22 | | 第六节 | 股东会的表决和决议 25 | | 第五章 | 董事会 29 | | 第一节 | 董事 29 | | 第二节 | 独立董事 34 | | 第三节 | 董事会 36 | | 第四节 | 董事会专门委员会 40 | | 第六章 | 经理及其他高级管理人员 45 | | 第七章 | 财务会计制度、利润分配和审计 47 | | 第一节 | 财务会计制度、利润分配 47 | | 第二节 | 内部审计 51 | | --- | --- | | 第三节 | 会计师事务所的聘任 5 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-041 爱博诺德（北京）医疗科技股份有限公司 关于选举董事长、董事会专门委员会委员及聘任公司 高级管理人员、证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）于 2025 年 5 月 29 日召开职工代表大会选举产生了第三届董事会职工代表董事，并于 2025 年 6 月 19 日召开 2024 年年度股东会，选举产生了第三届董事会非职工代表董事， 共同组成公司第三届董事会，任期自 2024 年年度股东会审议通过之日起三年。 同日，在股东会完成董事会换届选举后，公司召开第三届董事会第一次会议， 分别审议通过了《关于选举公司第三届董事会董事长的议案》《关于选举公司第 三届董事会专门委员会委员的议案》《关于聘任公司高级管理人员的议案》和 《关于聘任公司证券事务代表的议案》，选举产生了董事长和董事会各专门委员 会委员，并聘任公司新一届高级管理人员及证券事务代表。现将具体情况公告如 下： 一、选举 ...

爱博诺德（北京）医疗科技股份有限公司 关于变更注册资本、修订《公司章程》并办理工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）于 2025 年 6 月 19 日召开第三届董事会第一次会议，审议通过了《关于变更注册资本、修订< 公司章程>并办理工商变更登记的议案》。根据公司 2020 年年度股东大会、2023 年年度股东大会以及 2024 年年度股东会对董事会的授权，本次修订《公司章程》 并办理工商变更登记无需再次提交公司股东会审议。现将有关情况公告如下： 一、公司注册资本变更情况 （一）公司根据中国证券监督管理委员会《关于同意爱博诺德（北京）医疗 科技股份有限公司向特定对象发行股票注册的批复》（证监许可〔2025〕774 号），向 8 名特定对象发行人民币普通股（A 股）股票 3,593,615 股，并于 2025 年 5 月 12 日在中国证券登记结算有限责任公司上海分公司办理完毕股份登记手续。 公司的注册资本由人民币 189,544,528 元 ...